Lymphedema can occur after any cancer or its treatment that affects lymph node drainage. It has been reported to occur within days and up to 30 years after treatment for breast cancer. Lymphedema is a condition characterized by the swelling of body parts, usually the arms or legs, due to the accumulation of lymphatic fluid. Several factors can contribute to a rise in the number of lymphedema cases. One of these is the increasing geriatric population. As the global population ages, there is an increased risk of developing lymphedema, as it is more common in older individuals.
The high prevalence of the disease would lead to increased demand for lymphedema treatment and thus, there will be a surge in R&D for timely treatment of the patients, with funds being granted by private organizations and government organizations. It would also ensure the safe health of the patients. This aspect would deliver positive growth in the market
Access Full Report @ https://www.databridgemarketresearch.com/fr/reports/global-lymphedema-treatment-market
Data Bridge Market Research analyzes that the Global Lymphedema Treatment Market is expected to grow with a CAGR of 9.8% in the forecast period of 2023 to 2030 and is expected to reach USD 1,866,576.80 thousand by 2030. The compression therapy segment is projected to propel the market growth due to rising pet diseases.
Key Findings of the Stud
Increasing Drug Approvals
The global lymphedema treatment market has witnessed numerous drug approvals in past years driven by the increasing fatality rate of the disease. Increasing drug approvals will ramp up the demand for the market.
Increasing regulatory endorsements for lymphedema-related drugs and recombinant products will constitute an increase in the market value in the coming years.
The companies are increasing their product portfolio with combination drug products to enhance their business in various dimensions. Therefore, increasing drug approvals is expected to create a great opportunity for market growth.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Thousand
|
|
Segments Covered
|
Treatment Type (Compression Therapy, Surgery, Drug Therapy, Laser Therapy, and Others), Type (Primary Lymphedema and Secondary Lymphedema), Affected Area (Genitalia, Lower Extremity, and Upper Extremity), Age Group (Adult, Pediatric and Geriatric), Route of Administration (Oral, Injectable, and Topical), End User (Hospital, Ambulatory Surgical Centres, Speciality Clinics, and Others), Distribution Channel (Direct Tender, Pharmacy Stores, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, United Kingdom, Italy, Russia, Spain, Turkey, Netherlands, Switzerland, Belgium, Poland, Austria. Hungary, Norway, Ireland, Lithuania, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, U.A.E., Egypt, Kuwait, Israel, and Rest of Middle East and Africa
|
|
Market Players Covered
|
Tactile Medical (U.S.), Essity (BSN medical GmbH) (Germany), 3M (U.S.), Cardinal Health (U.S.), Lohmann & Rauscher GmbH & Co. KG (Germany), PAUL HARTMANN AG (Germany), medi GmbH & Co. KG (Germany), Smith+Nephew (U.K.), BIOCOMPRESSION SYSTEMS (U.S.), Mego Afek ltd. (Israel), SIGVARIS GROUP (U.S.), KOYA MEDICAL (U.S.), AIROS Medical, Inc. (U.S.), ConvaTec Inc. (U.K.), Juzo (Germany), Huntleigh Healthcare Limited. (U.K.), Herantis Pharma Plc (Finland), Avet Pharmaceuticals Inc. (U.S.), ThermoTek Inc (U.S.), and Sanyleg Srl (Italy) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
The global lymphedema treatment market is segmented into seven notable segments based on treatment type, type, affected area, age group, route of administration, end user, and distribution channel.
- On the basis of treatment type, the market is segmented into Compression Therapy, surgery, drug therapy, laser therapy, and others.
In 2023, the compression therapy segment is expected to dominate the global lymphedema treatment market
In 2023, the compression therapy segment is expected to dominate the market with a 67.09% market share because this effectively manages the disease symptoms with the rising demand for this treatment in the market.
- On the basis of type, the market is segmented into secondary lymphedema and primary lymphedema.
In 2023, the secondary lymphedema segment is expected to dominate the global lymphedema treatment market
In 2023, the secondary lymphedema segment is expected to dominate the market with a 78.71% market share because secondary lymphedema is the most common lymphedema among the population.
- On the basis of mode of purchase, the market is segmented into prescription based and OTC. In 2023, the prescription-based segment is expected to dominate the market with a 69.26% market share.
- On the basis of the affected area, the market is segmented into lower extremity, upper extremity, and genitalia. In 2023, the lower extremity segment is expected to dominate the market with 52.94% market share.
- On the basis of age group, the market is segmented into adult, geriatric, and pediatric. In 2023, the adult segment is expected to dominate the market with a 50.93% market share.
- On the basis of route of administration, the market is segmented into oral, injectable, and topical. In 2023, the oral segment is expected to dominate the market with a 52.02% market share.
- On the basis of end user, the market is segmented into hospital, speciality clinics, ambulatory surgical centers, and others. In 2023, the hospital segment is expected to dominate the market with a 53.59% market share.
- On the basis of distribution channel, the market is segmented into pharmacy stores, direct tender, and others. In 2023, the pharmacy stores segment is expected to dominate the market with a 52.51% market share.
Major Players
Data Bridge Market Research recognizes the following companies as the market players in the global lymphedema treatment market that include Tactile Medical (U.S.), Essity (BSN medical GmbH) (Germany), 3M (U.S.), Cardinal Health (U.S.), Lohmann & Rauscher GmbH & Co. KG (Germany), among others.
Market Developments
- In June 2021, InfuSystem Holdings, Inc. announced that it has entered into a joint agreement with Bio Compression Systems, Inc. whereby InfuSystem will add Lymphedema Therapy to its Integrated Therapy Service (“ITS”) platform facilities. These boosted sales of both companies thereby helping in revenue generation.
- In September 2020, Paul Hartmann AG formed partnerships with Apollo Hospitals Group in India and West China Hospital to focus on the operation of wound care clinics and ambulances, medical training, and products and services. This step helped the company to spread its wings in the Asia-Pacific market.
- In April 2020, L&R Group enhanced its position in the compression market - L&R acquired assets of French compression expert MTA. This acquisition allowed L&R to expand its product portfolio for venous insufficiency and lymphedema treatments and thus strengthened its market position in France.
- In August 2019, Paul Hartmann AG announced the acquisition of Safran Coating from Safran SA. This acquisition helped the company to increase its product portfolio.
- In September 2018, SIGVARIS announced the introduction of SECURE, an innovative garment featuring graduated compression and containment properties for the management of advanced venous edema, lymphedema, post-surgical edema, and general edema. This app launch boosted the market growth by creating awareness among people.
Regional Analysis
Geographically, the countries covered in the global lymphedema treatment market report are U.S., Canada, Mexico, Germany, France, United Kingdom, Italy, Russia, Spain, Turkey, Netherlands, Switzerland, Belgium, Poland, Austria. Hungary, Norway, Ireland, Lithuania, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, U.A.E., Egypt, Kuwait, Israel, and Rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
North America is expected to dominate the global lymphedema treatment market
North America is expected to dominate the market due to the strong presence of market players in the region and the rising prevalence of lymphedema diseases.
Asia-Pacific is expected to be the fastest growing region in the forecast period of 2023 to 2030.
Asia-Pacific is expected to grow with the highest growth rate in the forecast period due to increasing awareness of IgG4-related disease as well as rising disposable income in the region.
For more detailed information about the global lymphedema treatment market report, click here – https://www.databridgemarketresearch.com/fr/reports/global-lymphedema-treatment-market
